Edap Tms SA (NASDAQ:EDAP) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.

Analysts have set a 12 month consensus price objective of $6.50 for the company and are forecasting that the company will post $0.01 EPS for the current quarter, according to Zacks. Zacks has also given Edap Tms an industry rank of 163 out of 265 based on the ratings given to its competitors.

A number of brokerages have recently issued reports on EDAP. Zacks Investment Research upgraded Edap Tms from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a report on Wednesday, January 10th. ValuEngine cut Edap Tms from a “hold” rating to a “sell” rating in a report on Sunday, December 31st. Finally, HC Wainwright restated a “buy” rating and set a $6.50 price objective on shares of Edap Tms in a report on Monday, October 9th.

Several large investors have recently modified their holdings of EDAP. Virtu KCG Holdings LLC acquired a new stake in shares of Edap Tms in the second quarter valued at approximately $117,000. Archon Capital Management LLC raised its position in shares of Edap Tms by 12.5% in the third quarter. Archon Capital Management LLC now owns 843,489 shares of the medical equipment provider’s stock valued at $2,514,000 after buying an additional 93,762 shares in the last quarter. Finally, Essex Investment Management Co. LLC raised its position in shares of Edap Tms by 520.2% in the third quarter. Essex Investment Management Co. LLC now owns 323,528 shares of the medical equipment provider’s stock valued at $964,000 after buying an additional 271,367 shares in the last quarter. Institutional investors own 10.34% of the company’s stock.

Edap Tms (NASDAQ EDAP) traded up $0.16 during trading on Wednesday, reaching $2.81. The company had a trading volume of 152,100 shares, compared to its average volume of 51,550. Edap Tms has a fifty-two week low of $2.25 and a fifty-two week high of $3.85. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.96 and a quick ratio of 2.35. The company has a market capitalization of $76.85, a PE ratio of -35.12 and a beta of 1.02.

Edap Tms (NASDAQ:EDAP) last posted its quarterly earnings results on Wednesday, November 15th. The medical equipment provider reported ($0.02) EPS for the quarter, hitting analysts’ consensus estimates of ($0.02). Edap Tms had a positive return on equity of 7.85% and a negative net margin of 5.36%. The business had revenue of $8.44 million during the quarter, compared to analysts’ expectations of $11.05 million. The business’s revenue was down 5.6% compared to the same quarter last year. sell-side analysts anticipate that Edap Tms will post -0.01 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2018/01/17/edap-tms-sa-edap-given-average-recommendation-of-strong-buy-by-brokerages.html.

About Edap Tms

EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.

Get a free copy of the Zacks research report on Edap Tms (EDAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.